Induction of a regenerative microenvironment in skeletal muscle is sufficient to induce embryonal rhabdomyosarcoma in p53-deficient mice

Journal of Pathology

Volumn 226, Issue 1, 2012, Pages 40-49

  Camboni, Marybeth ^a   Hammond, Sue ^b   Martin, Laura T ^a,b   Martin, Paul T ^a,b  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

mdx; muscular dystrophy; p53; rhabdomyosarcoma; tumour microenvironment

Indexed keywords

CARDIOTOXIN; DYSTROPHIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA PROTEIN; SOMATOMEDIN B;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CONTROLLED STUDY; EMBRYONAL RHABDOMYOSARCOMA; ENZYME PHOSPHORYLATION; FEMALE; GASTROCNEMIUS MUSCLE; GENE DELETION; GENE LOSS; GENE OVEREXPRESSION; HISTOPATHOLOGY; MALE; MISSENSE MUTATION; MOUSE; MUSCLE REGENERATION; MUSCULAR DYSTROPHY; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE; TUMOR MICROENVIRONMENT; WILD TYPE;

ANIMALS; MICE; MICE, INBRED MDX; MICE, KNOCKOUT; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; REGENERATION; RHABDOMYOSARCOMA, EMBRYONAL; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR PROTEIN P53;

EID: 82755192941     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2996     Document Type: Article

References (45)

1. Arndt CA, Crist WM,. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999; 341: 342-352.
2. Parham DM, Ellison DA,. Rhabdomyosarcomas in adults and children: an update. Arch Pathol Lab Med 2006; 130: 1454-1465. (Pubitemid 44520712)
3. Morotti RA, Nicol KK, Parham DM, et al., An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children's Oncology Group experience. Am J Surg Pathol 2006; 30: 962-968. (Pubitemid 44264944)
4. Hettmer S, Wagers AJ,. Muscling in: Uncovering the origins of rhabdomyosarcoma. Nat Med 2010; 16: 171-173.
5. Charytonowicz E, Cordon-Cardo C, Matushansky I, et al., Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell? Cancer Lett 2009; 279: 126-136.
6. Kikuchi K, Rubin BP, Keller C,. Developmental origins of fusion-negative rhabdomyosarcomas. Curr Top Dev Biol 2011; 96: 33-56.
7. Davis RJ, D'Cruz CM, Lovell MA, et al., Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 1994; 54: 2869-2872. (Pubitemid 24187765)
8. Barr FG, Galili N, Holick J, et al., Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993; 3: 113-117. (Pubitemid 23079791)
9. Barr FG,. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 2001; 20: 5736-5746. (Pubitemid 32928111)
10. Koufos A, Hansen MF, Copeland NG, et al., Loss of heterozygosity in three embryonal tumours suggests a common pathogenetic mechanism. Nature 1985; 316: 330-334. (Pubitemid 15237805)
11. Anderson J, Gordon A, McManus A, et al., Disruption of imprinted genes at chromosome region 11p15.5 in paediatric rhabdomyosarcoma. Neoplasia 1999; 1: 340-348.
12. Keller C, Arenkiel BR, Coffin CM, et al., Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 2004; 18: 2614-2626. (Pubitemid 39453101)
13. Keller C, Hansen MS, Coffin CM, et al., Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin. Genes Dev 2004; 18: 2608-2613. (Pubitemid 39453100)
14. Galindo RL, Allport JA, Olson EN,. A Drosophila model of the rhabdomyosarcoma initiator PAX7-FKHR. Proc Natl Acad Sci USA 2006; 103: 13439-13444. (Pubitemid 44380126)
15. Ren YX, Finckenstein FG, Abdueva DA, et al., Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. Cancer Res 2008; 68: 6587-6597.
16. Nanni P, Nicoletti G, De Giovanni C, et al., Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice. Cancer Res 2003; 63: 2728-2732. (Pubitemid 36667140)
17. Tsumura H, Yoshida T, Saito H, et al., Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice. Oncogene 2006; 25: 7673-7679. (Pubitemid 44967962)
18. Langenau DM, Keefe MD, Storer NY, et al., Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev 2007; 21: 1382-1395. (Pubitemid 46871041)
19. Eichenmuller M, Bauer R, Von Schweinitz D, et al., Hedgehog-independent overexpression of transforming growth factor-β1 in rhabdomyosarcoma of Patched1 mutant mice. Int J Oncol 2007; 31: 405-412.
20. Lee Y, Kawagoe R, Sasai K, et al., Loss of suppressor-of-fused function promotes tumorigenesis. Oncogene 2007; 26: 6442-6447. (Pubitemid 47494220)
21. Sharp R, Recio JA, Jhappan C, et al., Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat Med 2002; 8: 1276-1280. (Pubitemid 35373560)
22. Rubin BP, Nishijo K, Chen HI, et al., Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell 2011; 19: 177-191.
23. Fernandez K, Serinagaoglu Y, Hammond S, et al., Mice lacking dystrophin or α-sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts. Am J Pathol 2010; 176: 416-434.
24. Chamberlain JS, Metzger J, Reyes M, et al., Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J 2007; 21: 2195-2204. (Pubitemid 47026454)
25. Schmidt WM, Uddin MH, Dysek S, et al., DNA damage, somatic aneuploidy, and malignant sarcoma susceptibility in muscular dystrophies. PLoS Genet 2011; 7: e1002042.
26. Sicinski P, Geng Y, Ryder-Cook AS, et al., The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 1989; 244: 1578-1580. (Pubitemid 19189735)
27. Duclos F, Straub V, Moore SA, et al., Progressive muscular dystrophy in α-sarcoglycan-deficient mice. J Cell Biol 1998; 142: 1461-1471. (Pubitemid 28452596)
28. Matsumura K, Ervasti JM, Ohlendieck K, et al., Association of dystrophin-related protein with dystrophin-associated proteins in mdx mouse muscle. Nature 1992; 360: 588-591. (Pubitemid 23000708)
29. De la Porte S, Morin S, Koenig J,. Characteristics of skeletal muscle in mdx mutant mice. Int Rev Cytol 1999; 191: 99-148. (Pubitemid 29250907)
30. Martin LT, Glass M, Dosunmu E, et al., Altered expression of natively glycosylated α-dystroglycan in pediatric solid tumors. Hum Pathol 2007; 38: 1657-1668. (Pubitemid 47589088)
31. Nguyen HH, Jayasinha V, Xia B, et al., Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice. Proc Natl Acad Sci USA 2002; 99: 5616-5621. (Pubitemid 34411598)
32. Xu R, DeVries S, Camboni M, et al., Overexpression of Galgt2 reduces dystrophic pathology in the skeletal muscles of α-sarcoglycan-deficient mice. Am J Pathol 2009; 175: 235-247.
33. Jacks T, Remington L, Williams BO, et al., Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994; 4: 1-7.
34. Stasik CJ, Tawfik O,. Malignant peripheral nerve sheath tumor with rhabdomyosarcomatous differentiation (malignant triton tumor). Arch Pathol Lab Med 2006; 130: 1878-1881. (Pubitemid 44906971)
35. Tidball JG, Villalta SA,. Regulatory interactions between muscle and the immune system during muscle regeneration. Am J Physiol Regul Integr Comp Physiol 2010; 298: R1173-1187.
36. Hirata A, Masuda S, Tamura T, et al., Expression profiling of cytokines and related genes in regenerating skeletal muscle after cardiotoxin injection: a role for osteopontin. Am J Pathol 2003; 163: 203-215. (Pubitemid 36759605)
37. White JD, Rachel C, Vermeulen R, et al., The role of p53 in vivo during skeletal muscle post-natal development and regeneration: studies in p53 knockout mice. Int J Dev Biol 2002; 46: 577-582. (Pubitemid 36841027)
38. Makawita S, Ho M, Durbin AD, et al., Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors. Pediatr Dev Pathol 2009; 12: 127-135.
39. Makawita S, Ho M, Durbin AD, et al., Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors. Pediat Dev Pathol Offic J Soc Pediat Pathol Paediat Pathol Soc 2009; 12: 127-135.
40. Bakay M, Zhao P, Chen J, et al., A web-accessible complete transcriptome of normal human and DMD muscle. Neuromusc Disord 2002; 12 (suppl 1): S125-141. (Pubitemid 36158783)
41. Boer JM, de Meijer EJ, Mank EM, et al., Expression profiling in stably regenerating skeletal muscle of dystrophin-deficient mdx mice. Neuromusc Disord 2002; 12 (suppl 1): S118-124. (Pubitemid 36158782)
42. Goetsch SC, Hawke TJ, Gallardo TD, et al., Transcriptional profiling and regulation of the extracellular matrix during muscle regeneration. Physiol Genom 2003; 14: 261-271. (Pubitemid 37345234)
43. Li FP, Fraumeni JF Jr,. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 1969; 43: 1365-1373.
44. Whitehead NP, Yeung EW, Allen DG,. Muscle damage in mdx (dystrophic) mice: role of calcium and reactive oxygen species. Clin Exp Pharmacol Physiol 2006; 33: 657-662. (Pubitemid 43894030)
45. Bischoff R,. Satellite Cells in Myology, 3rd edn, Franzini-Armstrong C, Engel A, (eds). McGraw-Hill: New York, 2004; 66-86.